More about the combination of rituximab, cyclosporine and dexamethasone in the treatment of chronic ITP. A useful option on an environment with limited resources

Abstract

Treatment of chronic primary immune thrombocytopenia (ITP) is challenging especially with limited resources and therapy-related complications. This prospective interventional study assessed the efficacy and safety of triple therapy(TT4); a combination treatment of oral dexamethasone 40 mg for days1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days and intravenous rituximab 100 mg for days7,14,21 and 28 among 40 patients with ITP who failed previous 2 or more treatment options. Our aim was to maintain platelet count ≥ 30 X 10⁹/L without any obvious bleeding at any point in the study. Platelet counts were assessed weekly for a month then monthly for 2 years to evaluate the long-term response. TT4 was well tolerated and induced a good response with a significant increase in the mean platelet count after the 1^st, 2^nd, 3^rd, and 4^thweek compared to the baseline. Patients with mean platelet count ≥ 30 X 10⁹/L at the 6^th month were 75% (30/40 patients). Treatment free survivals (TFS) at 12 and 24 months were 93.3% (28/30 patients) and 80% (24/30 patients) respectively. TT4 is an effective treatment option that maintained platelet count in the desired level and induced a higher sustained response, especially in an environment with limited resources.

Keywords:

• Bleeding
• immune thrombocytopenia
• Platelet
• triple therapy

Author contributions

AFT and SMM designed the study, analyzed the data, wrote the manuscript. collected data, revised the paper and approved the final version.

Conflict-of-Interest

The authors have no conflict of interests.

Informed consent

Informed consent was obtained from all individual participants included in the study. Research involving human participants